LON:CIZ Cizzle Biotechnology (CIZ) Share Price, News & Analysis GBX 1.33 -0.07 (-5.29%) As of 08/8/2025 11:18 AM Eastern Add Share Share Stock Analysis Stock AnalysisChartDividendHoldingsBuy This Stock About Cizzle Biotechnology (LON:CIZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cizzle Biotechnology alerts:Sign Up Key Stats Today's Range 1.20▼ 1.5050-Day Range 1.33▼ 252-Week Range 1.20▼ 2.69Volume2.38 million shsAverage Volume1.14 million shsMarket Capitalization£5.23 millionAssets Under Management£48.98 millionDividend Yield85.22%Net Expense Ratio0.46%Aggregate RatingN/A ETF Overview Cizzle Biotechnology Holdings Plc, together with its subsidiaries, engages in the development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom. Read More Cizzle Biotechnology ExpensesTypeCIZLarge Cap ETFsEquity ETFsLON ETFsAll ETFsManagement Fee0.40%0.58%0.56%0.45%0.53%Other Expenses0.25%0.27%0.56%0.25%0.56%Total Expense0.66%0.65%0.76%0.54%0.73%Fee Waiver-0.20%-0.23%-0.66%-0.20%-0.63%Net Expense0.46%0.62%0.63%0.47%0.60% Receive CIZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cizzle Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address CIZ ETF News HeadlinesCizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung CancerJuly 9, 2025 | finance.yahoo.comCizzle Bio Expands Global Reach with Cayman Islands Launch of Biomarker Blood Tests for Lung and Gastric CancersMay 29, 2025 | morningstar.comMGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live. | Priority Gold (Ad)TRADING UPDATES: GetsBusy backs sales outlook; Cizzle raises fundsMay 20, 2025 | lse.co.ukCizzle Brands CEO talks tariffs and strategies with health-focused product lineMay 2, 2025 | msn.comCizzle Biotech Share Chat (CIZ)December 14, 2024 | lse.co.ukSee More Headlines CIZ ETF - Frequently Asked Questions How have CIZ shares performed this year? Cizzle Biotechnology's stock was trading at GBX 1.59 on January 1st, 2025. Since then, CIZ shares have decreased by 16.6% and is now trading at GBX 1.33. How were Cizzle Biotechnology's earnings last quarter? Cizzle Biotechnology Holdings Plc (LON:CIZ) announced its earnings results on Wednesday, April, 30th. The company reported ($0.60) earnings per share for the quarter. How do I buy shares of Cizzle Biotechnology? Shares of CIZ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Cizzle Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cizzle Biotechnology investors own include Progressive (PGR), Qorvo (QRVO), TAL Education Group (TAL), Teekay Tankers (TNK), Waters (WAT), Preferred Apartment Communities (APTS) and Baidu (BIDU). Fund Details IssuerVictory Capital Management Fund NameVictoryShares Developed Enhanced Volatility Wtd ETF Tax ClassificationRegulated Investment Company Stock ExchangeLONCurrent SymbolLON:CIZ Inception Date9/30/2014 Fund ManagerMannik Dhillon, Stephen Hammers Webwww.cizzlebiotechnology.com Phone44-20-3934-6630Fund Focus Asset ClassEquity BenchmarkNasdaq Victory?International 500 Long/Cash Volatility Weighted Index CategorySize and Style FocusLarge Cap Development LevelDeveloped Markets RegionGlobal Ex-U.S. Number of Holdings505 Fund Statistics Assets Under Management$48.98 million Average Daily Volume$9.24 thousand Discount/Premium0.17% Administrator, Advisor and Custodian AdministratorVictory Capital Management Inc. AdvisorVictory Capital Management Inc. CustodianCitibank, N.A. DistributorForeside Fund Services, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerRBC Capital Markets Options OptionableN/A Short Interest15,600 shs Miscellaneous Outstanding Shares394,139,773Beta0.38 Creation Unit50,000 Creation Fee$4,500.00 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 4 CIZ HoldingsFederated Treasury Obligations FundHolding Weight: 100.00%China Common Rich RenHolding Weight: 0.00%Constellation Software InHolding Weight: 0.00%EVRAZ PLCHolding Weight: 0.00%Full Holdings DetailsCIZ Sector ExposureCIZ Industry Exposure This page (LON:CIZ) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cizzle Biotechnology Holdings Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cizzle Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
